Duchenne muscular dystrophy (DMD) is a hereditary, progressive muscular disorder inherited in an X-linked recessive pattern (Xp21). It typically manifests in childhood and follows a severe, rapid progression. Only males are affected, while females are usually carriers. Given the genetic nature of DMD, genetic counseling is an essential service for individuals affected by or at risk of carrying the disease. This service provides not only crucial medical information but also psychosocial support and ongoing management for both patients and their families. Since the discovery of the dystrophin gene in 1987, advancements in molecular genetics have made it possible to precisely identify the genes responsible for many neuromuscular diseases. These developments have revolutionized diagnosis, prognosis, and most importantly, genetic counseling, offering significant benefits for both patients and their families. To highlight the significance of these advancements, this case report focuses on a 10-year-old boy (Y) diagnosed with DMD. It emphasizes the familial nature of the disease, with Y’s two brothers, three cousins, and two maternal uncles also affected, underscoring the inherited pattern of DMD. This reinforces the critical need for early intervention, particularly in regions with high consanguinity, such as North Africa and the Middle East, where genetic counseling and prenatal diagnosis are even more essential. Additionally, the report explores the clinical presentation, diagnostic findings, and promising emerging treatments, including RNA-based therapies, which may play a key role in the future management of DMD. In light of the above, this study underscores the importance of prenatal diagnosis and genetic counseling, particularly in regions like Morocco, where consanguinity rates are notably high. By focusing on preconception care and early genetic intervention, families can be better informed, leading to more effective disease management and support.
References
[1]
El Goundali, K., Chebabe, M., Zahra Laamiri, F. and Hilali, A. (2022) The Determinants of Consanguineous Marriages among the Arab Population: A Systematic Review. Iranian Journal of Public Health, 51, 253-265. https://doi.org/10.18502/ijph.v51i2.8679
[2]
Dahbi, N., El khair, A., Cheffi, K., Habibeddine, L., Talbi, J., Hilali, A., et al. (2024) Consanguinity, Complex Diseases and Congenital Disabilities in the Souss Population (Southern Morocco): A Cross-Sectional Survey. Egyptian Journal of Medical Human Genetics, 25, Article No. 27. https://doi.org/10.1186/s43042-024-00490-w
Van Essen, A.J., Verheij, J.B.G.M., Reefhuis, J., Fidler, V., Begeer, J.H., de Visser, M., and ten Kate, L.P. (1997) The Natural History of Duchenne Muscular Dystrophy. Analysis of Data from a Dutch Survey and Review of Age Related Events. Doctoral Thesis, Groningen State University. (Unpublished)
[5]
Fernandez, C., Halbert, C., Maues de Paula, A., Figarella-Branger, D., Chabrol, B. and Pellissier, J. (2010) Dystrophies musculaires liées au gène DMD: Myopathie de Duchenne, myopathie de Becker, formes féminine et atypiques. EMC-Neurologie, 7, 1-15.
[6]
Desguerre, I., Mayer, M., Christov, C., Leturcq, F., Chelly, J. and Gherardi, R. (2009) Phenotypic Heterogeneity of Duchenne Myopathy and Prognosis Criteria. Archives de Pediatrie: Organe Officiel de la Societe Francaise de Pediatrie, 16, 681-683. https://doi.org/10.1016/s0929-693x(09)74110-7
[7]
Cox, G.F. and Kunkel, L.M. (1997) Dystrophies and Heart Disease. Current Opinion in Cardiology, 12, B67. https://doi.org/10.1097/00001573-199705000-00015
[8]
Brooke, M.H., Fenichel, G.M., Griggs, R.C., Mendell, J.R., Moxley, R., Miller, J.P., et al. (1983) Clinical Investigation in Duchenne Dystrophy: 2. Determination of the “Power” of Therapeutic Trials Based on the Natural History. Muscle & Nerve, 6, 91-103. https://doi.org/10.1002/mus.880060204
[9]
Miller, L.A., Romitti, P.A., Cunniff, C., Druschel, C., Mathews, K.D., Meaney, F.J., et al. (2006) The Muscular Dystrophy Surveillance Tracking and Research Network (MD Starnet): Surveillance Methodology. Birth Defects Research Part A: Clinical and Molecular Teratology, 76, 793-797. https://doi.org/10.1002/bdra.20279
[10]
Connuck, D.M., Sleeper, L.A., Colan, S.D., Cox, G.F., Towbin, J.A., Lowe, A.M., et al. (2008) Characteristics and Outcomes of Cardiomyopathy in Children with Duchenne or Becker Muscular Dystrophy: A Comparative Study from the Pediatric Cardiomyopathy Registry. American Heart Journal, 155, 998-1005. https://doi.org/10.1016/j.ahj.2008.01.018
[11]
Hoffman, E.P., Brown, R.H. and Kunkel, L.M. (1987) Dystrophin: The Protein Product of the Duchenne Muscular Dystrophy Locus. Cell, 51, 919-928. https://doi.org/10.1016/0092-8674(87)90579-4
[12]
Le Guen, Y.T., Le Gall, T., Laurent, V., d’Arbonneau, F., Braun, S. and Montier, T. (2021) Dystrophie musculaire de Duchenne: État actuel et perspectives thérapeutiques. Bulletin de l’Académie Nationale de Médecine, 205, 509-518. https://doi.org/10.1016/j.banm.2020.10.019
[13]
Bushby, K., Finkel, R., Birnkrant, D.J., Case, L.E., Clemens, P.R., Cripe, L., et al. (2010) Diagnosis and Management of Duchenne Muscular Dystrophy, Part 1: Diagnosis, and Pharmacological and Psychosocial Management. The Lancet Neurology, 9, 77-93. https://doi.org/10.1016/s1474-4422(09)70271-6
[14]
Moxley III, R.T., Ashwal, S., Pandya, S., Connolly, A., Florence, J., Mathews, K. and Wade, C. (2005) Practice Parameter: Corticosteroid Treatment of Duchenne Dystrophy: Report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. Neurology, 64, 13-20. https://doi.org/10.1212/01.WNL.0000148485.00049.B7
[15]
Moxley, R.T., Pandya, S., Ciafaloni, E., Fox, D.J. and Campbell, K. (2010) Change in Natural History of Duchenne Muscular Dystrophy with Long-Term Corticosteroid Treatment: Implications for Management. Journal of Child Neurology, 25, 1116-1129. https://doi.org/10.1177/0883073810371004
[16]
Nascimento Osorio, A., Medina Cantillo, J., Camacho Salas, A., Madruga Garrido, M. and Vilchez Padilla, J.J. (2019) Consensus on the Diagnosis, Treatment and Follow-Up of Patients with Duchenne Muscular Dystrophy. Neurología, 34, 469-481. https://doi.org/10.1016/j.nrl.2018.01.001
[17]
Matthews, E., Brassington, R., Kuntzer, T., Jichi, F. and Manzur, A.Y. (2016) Corticosteroids for the Treatment of Duchenne Muscular Dystrophy. Cochrane Database of Systematic Reviews, 2016, CD003725. https://doi.org/10.1002/14651858.cd003725.pub4
[18]
Kariyawasam, D., D’Silva, A., Mowat, D., Russell, J., Sampaio, H., Jones, K., et al. (2022) Incidence of Duchenne Muscular Dystrophy in the Modern Era; an Australian Study. European Journal of Human Genetics, 30, 1398-1404. https://doi.org/10.1038/s41431-022-01138-2
[19]
Whalen, S., Jacquette, A. and Héron, D. (2014) Genetic Counselling for Neuromuscular Diseases Beginning in Childhood. Médecine Thérapeutique/Pédiatrie, 17, 23-33. https://doi.org/10.1684/mtp.2014.0509
[20]
Beksac, M.S., Tanacan, A., Aydin Hakli, D., Orgul, G., Soyak, B., Balci Hayta, B., et al. (2018) Gestational Outcomes of Pregnant Women Who Have Had Invasive Prenatal Testing for the Prenatal Diagnosis of Duchenne Muscular Dystrophy. Journal of Pregnancy, 2018, Article ID: 9718316. https://doi.org/10.1155/2018/9718316
[21]
Erasmus, S. (2009) Duchenne and Becker Muscular Dystrophy: Implications for At-Risk Individuals. Doctoral Thesis, University of the Witwatersrand.
[22]
Topaloglu, H. (2013) Epidemiology of Muscular Dystrophies in the Mediterranean Area. Acta Myologica, 32, 138-141. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4006280/
[23]
Rochdi, K., Barakat, A. and Saile, R. (2022) Inherited Myopathies in the Middle East and North Africa. Gene Reports, 29, Article ID: 101674. https://doi.org/10.1016/j.genrep.2022.101674
[24]
Desguerre, I. and Laugel, V. (2015) Diagnostic et histoire naturelle de la dystrophie musculaire de Duchenne. Archives de Pédiatrie, 22, 12S24-12S30. https://doi.org/10.1016/s0929-693x(16)30005-7
[25]
Koenig, M., Hoffman, E.P., Bertelson, C.J., Monaco, A.P., Feener, C. and Kunkel, L.M. (1987) Complete Cloning of the Duchenne Muscular Dystrophy (DMD) cDNA and Preliminary Genomic Organization of the DMD Gene in Normal and Affected Individuals. Cell, 50, 509-517. https://doi.org/10.1016/0092-8674(87)90504-6
[26]
Goemans, N.M., Tulinius, M., van den Akker, J.T., Burm, B.E., Ekhart, P.F., Heuvelmans, N., et al. (2011) Systemic Administration of PRO051 in Duchenne’s Muscular Dystrophy. New England Journal of Medicine, 364, 1513-1522. https://doi.org/10.1056/nejmoa1011367
[27]
Cirak, S., Arechavala-Gomeza, V., Guglieri, M., Feng, L., Torelli, S., Anthony, K., et al. (2011) Exon Skipping and Dystrophin Restoration in Patients with Duchenne Muscular Dystrophy after Systemic Phosphorodiamidate Morpholino Oligomer Treatment: An Open-Label, Phase 2, Dose-Escalation Study. The Lancet, 378, 595-605. https://doi.org/10.1016/s0140-6736(11)60756-3
